AU2012327223A1 - Assays, antibodies, immunogens and compositions related to 5-FU - Google Patents

Assays, antibodies, immunogens and compositions related to 5-FU Download PDF

Info

Publication number
AU2012327223A1
AU2012327223A1 AU2012327223A AU2012327223A AU2012327223A1 AU 2012327223 A1 AU2012327223 A1 AU 2012327223A1 AU 2012327223 A AU2012327223 A AU 2012327223A AU 2012327223 A AU2012327223 A AU 2012327223A AU 2012327223 A1 AU2012327223 A1 AU 2012327223A1
Authority
AU
Australia
Prior art keywords
antibody
sample
reactivity
assay
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012327223A
Other languages
English (en)
Inventor
Paul Q. Hu
Xiaofen HUANG
Reid W. Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Defined Diagnostics LLC
Original Assignee
Wellstat Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Diagnostics LLC filed Critical Wellstat Diagnostics LLC
Publication of AU2012327223A1 publication Critical patent/AU2012327223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
AU2012327223A 2011-11-30 2012-11-30 Assays, antibodies, immunogens and compositions related to 5-FU Abandoned AU2012327223A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161565281P 2011-11-30 2011-11-30
US61/565,281 2011-11-30
US201261665686P 2012-06-28 2012-06-28
US61/665,686 2012-06-28
PCT/US2012/067353 WO2013082463A2 (en) 2011-11-30 2012-11-30 Assays, antibodies, immunogens and compositions related to 5-fu

Publications (1)

Publication Number Publication Date
AU2012327223A1 true AU2012327223A1 (en) 2013-06-20

Family

ID=48536238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012327223A Abandoned AU2012327223A1 (en) 2011-11-30 2012-11-30 Assays, antibodies, immunogens and compositions related to 5-FU

Country Status (6)

Country Link
US (1) US9702869B2 (https=)
EP (1) EP2785736A4 (https=)
JP (1) JP2015502356A (https=)
AU (1) AU2012327223A1 (https=)
CA (1) CA2857645A1 (https=)
WO (1) WO2013082463A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10401368B2 (en) 2014-03-20 2019-09-03 Pdl Biopharma, Inc. Antibodies and methods for the detection of cell death
US11305010B2 (en) * 2016-01-21 2022-04-19 The Scripps Research Institute Synthetic opioid vaccine
JP6218916B1 (ja) * 2016-12-28 2017-10-25 Jsr株式会社 磁性粒子分散液
JP7104911B2 (ja) * 2018-01-31 2022-07-22 国立研究開発法人産業技術総合研究所 標的物質検出方法及び導波モードセンサ
CN111875587B (zh) * 2020-07-23 2021-07-13 湖南苏阳医疗科技有限公司 5-氟胞嘧啶衍生物、其制备方法及其在5-氟胞嘧啶免疫检测试剂中的应用
WO2022119937A1 (en) * 2020-12-03 2022-06-09 Ortho-Clinical Diagnostics, Inc. Lithium heparin as a blocking agent
CN113501877A (zh) * 2021-08-23 2021-10-15 苏州科铭生物技术有限公司 抗5-氟尿嘧啶单克隆抗体的制备方法、5-氟尿嘧啶的酶联免疫检测方法
CN114487059B (zh) * 2021-12-29 2022-11-25 苏州大学 一种电化学发光免疫传感器及其制备和应用
JP7709140B2 (ja) * 2022-03-01 2025-07-16 学校法人早稲田大学 小型非荷電分子の検出方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366862A (en) * 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
US20030017147A1 (en) 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
DE10020376A1 (de) * 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
WO2006044643A2 (en) * 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US20060177883A1 (en) 2005-02-08 2006-08-10 Saladax Biomedical Inc. 5-Fluoro-uracil immunoassay
AU2008330125B2 (en) * 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
CN101461948B (zh) * 2009-01-04 2011-12-14 广东药学院 一种叶酸介导的5-氟尿嘧啶白蛋白大分子前体药物及其制备方法和应用
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
CA2685842A1 (en) * 2009-07-16 2011-01-16 University College Cork, National University Of Ireland, Cork A method for the treatment of cancer
CA2768488A1 (en) 2009-07-17 2011-01-20 Myriad Genetics, Inc. Method of assaying 5-fu
ES2724975T3 (es) * 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada

Also Published As

Publication number Publication date
EP2785736A2 (en) 2014-10-08
EP2785736A4 (en) 2015-12-09
CA2857645A1 (en) 2013-06-06
US20150079612A1 (en) 2015-03-19
US9702869B2 (en) 2017-07-11
JP2015502356A (ja) 2015-01-22
WO2013082463A3 (en) 2013-08-15
WO2013082463A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
US9702869B2 (en) Assays, antibodies, immunogens and compositions related to 5-FU
JP7502549B2 (ja) 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
JP7014706B2 (ja) 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
CA2755219C (en) Antibodies binding to pivka-ii amino acids 13-27
JP2015527987A (ja) 薬物モニタリングのための抗トファシチニブ抗体およびその使用
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
WO2012018476A1 (en) Antibodies relating to pivka-ii and uses thereof
JP2022009080A (ja) 卵巣癌の検出および治療のための組成物および方法
EA037032B1 (ru) Применение и способ для профилактики или лечения рака пищевода с использованием композиции, содержащей прогастрин-связывающее антитело
US20130217145A1 (en) Antibodies which detect pivkaii and methods of use thereof
AU2019228339B2 (en) Progastrin as a biomarker for immunotherapy
US20240390509A1 (en) Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體
CA3092414C (en) Progastrin as a biomarker for immunotherapy
JP2024508222A (ja) 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法
CN119818701A (zh) 抗体药物偶联物及其医药用途
WO2025242039A1 (zh) 抗cdh17抗体、其抗体药物偶联物及其用途
TW202405010A (zh) 抗人類ｓｅｍａ７ａ抗體
TW202613168A (zh) 抗cdh17抗體、其抗體藥物偶聯物及其用途
EA050277B1 (ru) Способ диагностики in vitro рака пищевода и способ мониторинга эффективности его лечения

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application